-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the hypertensive drug market made waves again, Tianjin Lisheng Pharmaceutical's valsartan amlodipine tablets (I), Jiangxi Shimei Pharmaceutical's perdopri indapamide tablets and other 3 products were approved on the same day, since the beginning of this year, 32 hypertensive drugs (71 specifications) have been approved
.
According to data from Minai.
com, the terminal hypertension drug market of China's urban physical pharmacies will exceed 15 billion yuan in 2021, and it is expected to reach a new high in 2022, with 3 major products exceeding 1 billion and 4 domestic brands on the TOP20
.
Up to now, nearly 70 hypertensive drugs (more than 270 acceptance numbers) have been submitted for production under review under new classification, Chia Tai Tianqing Pharmaceutical Group, Chengdu Beite Pharmaceutical, etc.
are the first imitation, Guangzhou Poinsettia Pharmaceutical's amlodipine benzoate dry suspension and Shenzhen Salubris Pharmaceutical's alisartan amlodipine tablets are both improved new drugs and are expected to win the first in China
.
.
According to data from Minai.
com, the terminal hypertension drug market of China's urban physical pharmacies will exceed 15 billion yuan in 2021, and it is expected to reach a new high in 2022, with 3 major products exceeding 1 billion and 4 domestic brands on the TOP20
.
Up to now, nearly 70 hypertensive drugs (more than 270 acceptance numbers) have been submitted for production under review under new classification, Chia Tai Tianqing Pharmaceutical Group, Chengdu Beite Pharmaceutical, etc.
are the first imitation, Guangzhou Poinsettia Pharmaceutical's amlodipine benzoate dry suspension and Shenzhen Salubris Pharmaceutical's alisartan amlodipine tablets are both improved new drugs and are expected to win the first in China
.
Hypertensive drugs were "stacked" on the market, and Hengrui and Puli won the first in China
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
A few days ago, the hypertensive chemical drug market made waves again, Tianjin Lisheng Pharmaceutical's valsartan amlodipine tablets (I), Jiangxi Shimei Pharmaceutical's perindoprindapamide tablets, Beijing Yuanyan Pharmaceutical's olmesartan ester hydrochlorothiazide tablets were all approved as generic 4 categories, which are regarded as
evaluations.
evaluations.
Hypertension drugs approved since this year
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
Since the beginning of this year, 32 varieties (71 specifications) of hypertension drugs have been approved, among which valsartan amlodipine tablets (I.
), valsartan tablets and nifedipine controlled-release tablets are the most popular, and 5 or more enterprises have been approved
.
In addition, Jiangsu Hengrui Pharmaceutical's nimodipine oral solution, Hainan Puli Pharmaceutical's nitroprusside sodium injection, Sichuan Baili Pharmaceutical's enalapril maleate oral liquid and other 6 products are the first in China
.
Nimodipine is a dihydropyridine calcium channel blocker, which inhibits the contraction of vascular smooth muscle cells by inhibiting the entry of calcium ions into cells, and is easy to pass through the blood-brain barrier because of its high lipophilicity, thus having a strong effect
on cerebral arteries.
According to data from Minai.
com, the dosage forms of nimodipine that have been listed before this include tablets, capsules and injections, Hengrui Pharmaceutical's nimodipine oral solution is the first in China, and 4 enterprises such as Zhejiang Guojing Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical| Zhejiang Kangbei Pharmaceutical are under review
.
), valsartan tablets and nifedipine controlled-release tablets are the most popular, and 5 or more enterprises have been approved
.
In addition, Jiangsu Hengrui Pharmaceutical's nimodipine oral solution, Hainan Puli Pharmaceutical's nitroprusside sodium injection, Sichuan Baili Pharmaceutical's enalapril maleate oral liquid and other 6 products are the first in China
.
Nimodipine is a dihydropyridine calcium channel blocker, which inhibits the contraction of vascular smooth muscle cells by inhibiting the entry of calcium ions into cells, and is easy to pass through the blood-brain barrier because of its high lipophilicity, thus having a strong effect
on cerebral arteries.
According to data from Minai.
com, the dosage forms of nimodipine that have been listed before this include tablets, capsules and injections, Hengrui Pharmaceutical's nimodipine oral solution is the first in China, and 4 enterprises such as Zhejiang Guojing Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical| Zhejiang Kangbei Pharmaceutical are under review
.
3 major varieties of more than 1 billion are entrenched in the 10 billion market, and 4 domestic brands are listed in the TOP20
Sales of hypertensive drugs in China's urban physical pharmacies in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
According to data from Minai.
com, the terminal hypertensive drug market of China's urban physical pharmacies has steadily climbed in recent years, exceeding the 15 billion yuan mark in 2021, and is expected to reach a new high in 2022, with a year-on-year increase of more than 5%.
com, the terminal hypertensive drug market of China's urban physical pharmacies has steadily climbed in recent years, exceeding the 15 billion yuan mark in 2021, and is expected to reach a new high in 2022, with a year-on-year increase of more than 5%.
Market share of hypertensive drugs in China's urban physical pharmacies in 2022E
Source: Competition pattern of drug terminals in China's urban physical pharmacies
From the perspective of treatment subcategories, the total market share of the top 4 accounts for more than 95%, of which calcium channel blockers rank first, hypertension compound preparations and β-receptor blockers are growing rapidly, and the growth rate is expected to exceed 10%
in 2022.
in 2022.
2022E Top 20 hypertensive drug products in China's urban physical pharmacies (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
The total sales of TOP20 products exceeded 13 billion yuan, and amlodipine besylate tablets, levamlodipine besylate tablets and nifedipine controlled-release tablets all exceeded 1 billion yuan
.
The 20 products came from 4 best-selling treatment subgroups, including 6 calcium channel blockers and hypertension combination preparations, 5 drugs acting on the renin-angiotensin system, and 3 β-blockers
.
From the perspective of growth rate, nifedipine controlled-release tablets, metoprolol succinate sustained-release tablets, valsartan amlodipine tablets (I.
), irbesartan hydrochlorothiazide tablets, valsartan hydrochlorothiazide tablets, benazepril hydrochloride tablets, and losartan potassium hydrochlorothiazide tablets all increased by more than 10%.
Among the 7 products with a growth rate of more than 10%, 4 are hypertension compound preparations
.
.
The 20 products came from 4 best-selling treatment subgroups, including 6 calcium channel blockers and hypertension combination preparations, 5 drugs acting on the renin-angiotensin system, and 3 β-blockers
.
From the perspective of growth rate, nifedipine controlled-release tablets, metoprolol succinate sustained-release tablets, valsartan amlodipine tablets (I.
), irbesartan hydrochlorothiazide tablets, valsartan hydrochlorothiazide tablets, benazepril hydrochloride tablets, and losartan potassium hydrochlorothiazide tablets all increased by more than 10%.
Among the 7 products with a growth rate of more than 10%, 4 are hypertension compound preparations
.
2022E China Urban Physical Pharmacy Hypertensive Drug Brand TOP20 (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
Among the top 20 brands, foreign-funded pharmaceutical companies dominate, occupying eighty percent of the seats, and the domestic brands are only Lvoampipine besylate tablets from Schida Pharmaceutical Group (Jilin), compound reserpine triamterene tablets from China Resources Shuanghe Pharmaceutical, levamlodipine maleate tablets from Shiyi Pharmaceutical Ouyi Pharmaceutical, and nifedipine sustained-release tablets (II.
)
from Qingdao Huanghai Pharmaceutical.
In terms of numbers, Novartis has the most, with 5, followed by AstraZeneca, with 3.
)
from Qingdao Huanghai Pharmaceutical.
In terms of numbers, Novartis has the most, with 5, followed by AstraZeneca, with 3.
Poinsettia and Salubris improved new drugs are coming, and 15 first imitations will be born
Hypertension drug improvement new drug production status under review
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
There are currently no hypertension drugs approved and submitted for production under review in China
Source: Minai.
com China Declaration Progress (MED) database
com China Declaration Progress (MED) database
Up to now, nearly 70 hypertensive drugs (more than 270 acceptance numbers) are under review with the new classification, of which 15 varieties have not been approved for generic drugs in China, and the hypertension compound preparation sacubitril valsartan sodium tablets are the most sought-after, and more than 10 enterprises such as Chia Tai Tianqing Pharmaceutical Group, Chengdu Beite Pharmaceutical, and Petrochemical Group Ouyi Pharmaceutical have reported production
.
It is worth mentioning that this year, the improved new drugs of hypertension drugs have been reported for production one after another, and Guangzhou Poinsettia Pharmaceutical's amlodipine benzoate dry suspension and Shenzhen Salubris Pharmaceutical's alisartan amlodipine tablets are expected to win the first in China
.
.
It is worth mentioning that this year, the improved new drugs of hypertension drugs have been reported for production one after another, and Guangzhou Poinsettia Pharmaceutical's amlodipine benzoate dry suspension and Shenzhen Salubris Pharmaceutical's alisartan amlodipine tablets are expected to win the first in China
.
Amlodipine benzoate dry suspension is the first improved new drug declared for marketing by Guangzhou Poinsettia Pharmaceutical, and there is currently no amlodipine besylate and other salts suspension preparations in
China.
According to data from Minai.
com, the terminal sales scale of amlodipine in China's urban physical pharmacies has exceeded 2 billion yuan in recent years, and it is expected to increase by more than 5%
year-on-year in 2022.
China.
According to data from Minai.
com, the terminal sales scale of amlodipine in China's urban physical pharmacies has exceeded 2 billion yuan in recent years, and it is expected to increase by more than 5%
year-on-year in 2022.
Alisartan cilexetil amlodipine tablets are ARB/CCB combination preparations, suitable for patients
with essential hypertension with poor blood pressure control after alisartan cilexetil or amlodipine monotherapy.
Salubris said that after the product is listed, it will form a strategic synergy with the company's listed class 1.
1 antihypertensive drug Salubris (alisartan cilexetil tablets) to further enrich the company's innovative product pipeline in the cardiovascular field, cover a wider range of hypertensive patients, and enhance the company's comprehensive competitiveness
in the field of chronic diseases.
with essential hypertension with poor blood pressure control after alisartan cilexetil or amlodipine monotherapy.
Salubris said that after the product is listed, it will form a strategic synergy with the company's listed class 1.
1 antihypertensive drug Salubris (alisartan cilexetil tablets) to further enrich the company's innovative product pipeline in the cardiovascular field, cover a wider range of hypertensive patients, and enhance the company's comprehensive competitiveness
in the field of chronic diseases.
Source: Minainet database, company announcements, etc
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; All sales are based on the average retail price of the product
.
If there is any omission, welcome to correct!
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; All sales are based on the average retail price of the product
.
If there is any omission, welcome to correct!
